Nome |
# |
Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy, file dfa8b98e-1b78-748b-e053-3a05fe0a3a96
|
1.460
|
Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy : an international observational study, file dfa8b98e-1b86-748b-e053-3a05fe0a3a96
|
1.142
|
All-cause mortality in treated HIV-infected
adults with CD4 500/mm3 compared with
the general population : evidence from a large European observational cohort collaboration, file dfa8b990-b661-748b-e053-3a05fe0a3a96
|
765
|
Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens, file dfa8b98f-fb18-748b-e053-3a05fe0a3a96
|
646
|
Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006 : collaborative analysis of 13 HIV cohort studies, file dfa8b990-1261-748b-e053-3a05fe0a3a96
|
636
|
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries, file dfa8b98f-7852-748b-e053-3a05fe0a3a96
|
473
|
The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection, file dfa8b990-40e4-748b-e053-3a05fe0a3a96
|
458
|
Performance of genotypic tropism testing on proviral DNA in clinical practice : results from the DIVA study group, file dfa8b990-1874-748b-e053-3a05fe0a3a96
|
452
|
Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study)., file dfa8b9a5-77a7-748b-e053-3a05fe0a3a96
|
435
|
Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patients, file dfa8b990-c4f4-748b-e053-3a05fe0a3a96
|
395
|
Detrimental effect of atazanavir plasma concentrations on total serum bilirubin levels in the presence of UGT1A1 polymorphisms, file dfa8b98f-f3fd-748b-e053-3a05fe0a3a96
|
384
|
Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors, file dfa8b98e-1b54-748b-e053-3a05fe0a3a96
|
378
|
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen, file dfa8b99f-cd0c-748b-e053-3a05fe0a3a96
|
339
|
Italian consensus statement on management of HIV-infected individuals with advanced disease naive to antiretroviral therapy, file dfa8b98e-bbc6-748b-e053-3a05fe0a3a96
|
337
|
Risk of tuberculosis following HIV seroconversion in high-income countries, file dfa8b990-8f64-748b-e053-3a05fe0a3a96
|
322
|
Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus, file dfa8b9aa-33d0-748b-e053-3a05fe0a3a96
|
305
|
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy, file dfa8b991-2432-748b-e053-3a05fe0a3a96
|
296
|
What do the changing patterns of comorbidity burden in people living with HIV mean for long-term management? Perspectives from European HIV cohorts, file dfa8b9a4-dd83-748b-e053-3a05fe0a3a96
|
293
|
Reduced central memory CD4+ T cells and increased T-Cell activation characterise treatment-naive patients newly diagnosed at late stage of HIV infection, file dfa8b990-0a94-748b-e053-3a05fe0a3a96
|
281
|
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART, file dfa8b99e-1181-748b-e053-3a05fe0a3a96
|
275
|
One‐Year Cognitive Follow‐Up of COVID‐19 Hospitalized Patients, file 716b720a-6f43-4058-9740-62df85c978d5
|
272
|
Virologic and Immunologic Response to cART by HIV-1 Subtype in the CASCADE Collaboration, file dfa8b990-c4f5-748b-e053-3a05fe0a3a96
|
259
|
Survival outcomes and effect of early vs. deferred cART among HIV-infected patients diagnosed at the time of an AIDS-defining event: a cohort analysis, file dfa8b98f-a3ee-748b-e053-3a05fe0a3a96
|
247
|
Late presentation of HIV infection : a consensus definition, file dfa8b99d-83bf-748b-e053-3a05fe0a3a96
|
244
|
Is the rate of virological failure to cART continuing to decline in recent calendar years?, file dfa8b99e-53f0-748b-e053-3a05fe0a3a96
|
238
|
Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients, file dfa8b990-09e0-748b-e053-3a05fe0a3a96
|
236
|
Free light chains and the risk of nonmalignant AIDS events in HIV-infected patients treated with combination antiretroviral therapy, file dfa8b990-c3ee-748b-e053-3a05fe0a3a96
|
223
|
Effectiveness of switching to darunavir/cobicistat in virologically-suppressed HIV-positive patients receiving ritonavir-boosted protease inhibitor-based regimen : the "STORE" Study, file dfa8b9a1-3b51-748b-e053-3a05fe0a3a96
|
212
|
Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+ : CD8+ ratio, file dfa8b99b-327c-748b-e053-3a05fe0a3a96
|
210
|
T-Cell Phenotypes, Apoptosis and Inflammation in HIV+ Patients on Virologically Effective cART with Early Atherosclerosis, file dfa8b990-68f7-748b-e053-3a05fe0a3a96
|
209
|
Hepatitis c virus viremia increases the Incidence of chronic kidney disease in HIV-infected Patients, file dfa8b9a3-d5e4-748b-e053-3a05fe0a3a96
|
208
|
Increased risk of cardiovascular disease (CVD) with age in HIV-positive men : a comparison of the D: A: D CVD risk equation and general population CVD risk equations, file dfa8b99d-f8de-748b-e053-3a05fe0a3a96
|
207
|
Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America, file dfa8b992-65fb-748b-e053-3a05fe0a3a96
|
206
|
Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV : a multilevel analysis, file dfa8b990-0a10-748b-e053-3a05fe0a3a96
|
197
|
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population, file dfa8b9a3-2f62-748b-e053-3a05fe0a3a96
|
192
|
Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression : 48-week efficacy and safety results, file dfa8b991-92f4-748b-e053-3a05fe0a3a96
|
190
|
Cause-specific mortality in HIV-positive patients who survived ten years after starting antiretroviral therapy, file dfa8b99a-97f6-748b-e053-3a05fe0a3a96
|
188
|
Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients : results from the Icona Foundation study, file dfa8b991-2431-748b-e053-3a05fe0a3a96
|
186
|
Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals : The D: A: D Study, file dfa8b990-bbf6-748b-e053-3a05fe0a3a96
|
184
|
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort, file dfa8b99d-254b-748b-e053-3a05fe0a3a96
|
184
|
Stimulation of PBMC and Monocyte-Derived Macrophages via Toll-Like Receptor Activates Innate Immune Pathways in HIV-Infected Patients on Virally Suppressive Combination Antiretroviral Therapy, file dfa8b99c-9cac-748b-e053-3a05fe0a3a96
|
176
|
Predicting the short-term risk of diabetes in HIV-positive patients : the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study, file dfa8b990-b610-748b-e053-3a05fe0a3a96
|
175
|
CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE, file dfa8b990-b88a-748b-e053-3a05fe0a3a96
|
175
|
Is weak CD4+ gain in the course of suppressive combination antiretroviral therapy for HIV infection a current clinical challenge? A case report and brief review of the literature, file dfa8b99a-32f8-748b-e053-3a05fe0a3a96
|
170
|
Improvement of ALT decay kinetics by all-oral HCV treatment : role of NS5A inhibitors and differences with IFN-based regimens, file dfa8b99d-cc34-748b-e053-3a05fe0a3a96
|
168
|
Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy, file dfa8b98f-a2e2-748b-e053-3a05fe0a3a96
|
164
|
Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A. : a modelling study, file dfa8b999-b521-748b-e053-3a05fe0a3a96
|
161
|
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy : 48-Week results of a randomized trial, file dfa8b999-d10e-748b-e053-3a05fe0a3a96
|
161
|
Feasibility and effectiveness of indicator condition-guided testing for HIV : results from HIDES I (HIV Indicator Diseases across Europe Study), file dfa8b990-bbf0-748b-e053-3a05fe0a3a96
|
160
|
Invariant Natural Killer T (iNKT) cells in HAART-treated, HIV-positive patients with bone and cardiovascular impairment, file dfa8b994-2f68-748b-e053-3a05fe0a3a96
|
152
|
Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA, file dfa8b9a3-8569-748b-e053-3a05fe0a3a96
|
151
|
HPV infection in a cohort of HIV-positive men and women : prevalence of oncogenic genotypes and predictors of mucosal damage at genital and oral sites, file dfa8b991-2442-748b-e053-3a05fe0a3a96
|
149
|
HIV-Infected late presenter patients, file dfa8b990-0eb6-748b-e053-3a05fe0a3a96
|
147
|
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011, file dfa8b990-16b4-748b-e053-3a05fe0a3a96
|
144
|
Increased bone marrow interleukin-7 (IL-7)/IL-7R levels but reduced IL-7 responsiveness in HIV-Positive patients lacking CD4+ gain on antiviral therapy, file dfa8b98f-7070-748b-e053-3a05fe0a3a96
|
142
|
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI, file dfa8b98f-a81f-748b-e053-3a05fe0a3a96
|
142
|
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals : an observational cohort study, file dfa8b99b-3097-748b-e053-3a05fe0a3a96
|
142
|
Predictors of having a resistance test following confirmed virological failure of cART: data from EuroSIDA, file dfa8b990-2059-748b-e053-3a05fe0a3a96
|
140
|
Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders, file dfa8b990-bc6c-748b-e053-3a05fe0a3a96
|
140
|
Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population, file dfa8b99a-fe6e-748b-e053-3a05fe0a3a96
|
140
|
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir± ribavirin in HIV/HCV co-infected patients, file dfa8b99e-1836-748b-e053-3a05fe0a3a96
|
140
|
Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals : The Antiretroviral Therapy Cohort Collaboration, file dfa8b9a5-5b25-748b-e053-3a05fe0a3a96
|
140
|
The effect of switching to Maraviroc + Darunavir/ritonavir dual therapy in virologically suppressed patients on the progression of liver fibrosis, file dfa8b99d-c416-748b-e053-3a05fe0a3a96
|
138
|
Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy : A postauthorization noninterventional study, file dfa8b996-43f7-748b-e053-3a05fe0a3a96
|
136
|
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus, file dfa8b99e-304b-748b-e053-3a05fe0a3a96
|
136
|
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts : Data from the Icona Foundation Cohort, file dfa8b996-5ad3-748b-e053-3a05fe0a3a96
|
133
|
Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration, file dfa8b99a-a481-748b-e053-3a05fe0a3a96
|
131
|
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus, file dfa8b996-bae8-748b-e053-3a05fe0a3a96
|
130
|
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection : Results of an Italian Compassionate Use Program, file dfa8b99d-e5d0-748b-e053-3a05fe0a3a96
|
130
|
Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients, file dfa8b9a3-bc70-748b-e053-3a05fe0a3a96
|
129
|
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice, file dfa8b996-c666-748b-e053-3a05fe0a3a96
|
128
|
Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe : results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE), file dfa8b99a-a7a3-748b-e053-3a05fe0a3a96
|
128
|
Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients, file dfa8b99e-0a40-748b-e053-3a05fe0a3a96
|
128
|
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy, file dfa8b99c-e6d5-748b-e053-3a05fe0a3a96
|
127
|
Role of in vitro stimulation with lipopolysaccharide on T-Cell activation in HIV-infected antiretroviral-treated patients, file dfa8b990-1871-748b-e053-3a05fe0a3a96
|
126
|
Cognitive Neuro-Rehabilitation of HIV-Associated Neurocognitive Disorders : Case Reports of A New Computer-Based Restorative Approach In 3 Hiv-Positive Cart-Treated Patients, file dfa8b999-5cce-748b-e053-3a05fe0a3a96
|
125
|
Timing of antiretroviral therapy initiation after a first AIDS-defining event : temporal changes in clinical attitudes in the ICONA cohort, file dfa8b991-2214-748b-e053-3a05fe0a3a96
|
124
|
Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy, file dfa8b997-4e36-748b-e053-3a05fe0a3a96
|
124
|
Illness Representations of HIV Positive Patients Are Associated with Virologic Success, file dfa8b997-cd06-748b-e053-3a05fe0a3a96
|
123
|
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIRaben-1 subtype B and non-subtype B receiving a salvage regimen, file dfa8b99a-65c5-748b-e053-3a05fe0a3a96
|
123
|
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens, file dfa8b99b-27ae-748b-e053-3a05fe0a3a96
|
121
|
Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk : a prospective analysis of the D:A:D observational study, file dfa8b99a-98d5-748b-e053-3a05fe0a3a96
|
120
|
Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study, file dfa8b99b-807b-748b-e053-3a05fe0a3a96
|
120
|
Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America, file dfa8b99b-ff30-748b-e053-3a05fe0a3a96
|
120
|
Mucosal cell populations may contribute to peripheral immune abnormalities in HIV-infected subjects introducing cART with moderate immune-suppression, file dfa8b99e-df6e-748b-e053-3a05fe0a3a96
|
120
|
Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort, file dfa8b99a-06eb-748b-e053-3a05fe0a3a96
|
119
|
An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy, file dfa8b99e-33e1-748b-e053-3a05fe0a3a96
|
117
|
A376s in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy, file dfa8b9a3-9b58-748b-e053-3a05fe0a3a96
|
116
|
Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies, file dfa8b998-a850-748b-e053-3a05fe0a3a96
|
114
|
Antiretroviral drugs and risk of chronic alanine aminotransferase elevation in human immunodeficiency virus (HIV)-monoinfected persons: The data collection on adverse events of Anti-HIV drugs study, file dfa8b99b-4d3d-748b-e053-3a05fe0a3a96
|
113
|
The EuroSIDA study: 25 years of scientific achievements, file dfa8b9aa-4331-748b-e053-3a05fe0a3a96
|
113
|
Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord, file dfa8b99a-a719-748b-e053-3a05fe0a3a96
|
112
|
A 20-year-old girl with an unusual febrile illness, file dfa8b9a6-fb4c-748b-e053-3a05fe0a3a96
|
112
|
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy, file dfa8b996-a8d3-748b-e053-3a05fe0a3a96
|
111
|
Therapeutic Effect of Iron Citrate in Blocking Calcium Deposition in High Pi-Calcified VSMC: Role of Autophagy and Apoptosis, file dfa8b9a0-3cb6-748b-e053-3a05fe0a3a96
|
110
|
High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects Data from the ICONA Foundation Cohort, file dfa8b99a-a117-748b-e053-3a05fe0a3a96
|
108
|
Psychological outcomes after hospitalization for COVID-19: data from a multidisciplinary follow-up screening program for recovered patients, file dfa8b9a5-0a33-748b-e053-3a05fe0a3a96
|
108
|
The Many Faces of Covid-19 at a Glance: A University Hospital Multidisciplinary Account From Milan, Italy, file dfa8b9a5-cd28-748b-e053-3a05fe0a3a96
|
107
|
Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008 : data from the ICONA Foundation Study Cohort, file dfa8b99d-e5dc-748b-e053-3a05fe0a3a96
|
106
|
Association between abdominal aortic calcifications, bone mineral density and vertebral fractures in a cohort of HIV-positive patients, file dfa8b997-7b3b-748b-e053-3a05fe0a3a96
|
105
|
Totale |
22.334 |